Karin Schulze

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study

A. Kaufmann, T. Schwarz, D. Descamps, 2014, BJOG : an international journal of obstetrics and gynaecology.

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

P. Hillemanns, M. Dionne, F. Struyf, 2014, Human vaccines & immunotherapeutics.

O608 IMMUNE RESPONSE TO THE HPV‐16/18 AS04‐ADJUVANTED VACCINE ADMINISTERED AS A 2‐DOSE OR 3‐DOSE SCHEDULE UP TO 3 YEARS AFTER VACCINATION

P. Hillemanns, M. Dionne, F. Struyf, 2012 .

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

P. Hillemanns, M. Dionne, T. Schwarz, 2011, Human vaccines.

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

P. Hillemanns, M. Dionne, F. Struyf, 2015, Human vaccines & immunotherapeutics.

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

A. Schneider, T. Schwarz, D. Descamps, 2011, Human vaccines.